After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...